Pain Outcomes After Digital Amputation Using Tulavi Allay™ Nerve Cap

Recruiting Phase 2 Interventional Study
Neuroma Neuropathic Pain
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
22 and older
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Prevention
Participants needed
20 (estimated)
Sponsor
Massachusetts General Hospital · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
In 2016, one in five individuals in the United States (US) experienced chronic pain, and approximately 40% of them suffered from neuropathic pain. The physical and emotional burden on patients results in costs of billions of dollars annually. Digital amputations affect over 23,000 people each year in the US and may lead to neuropathic pain and neuroma formation in the transected nerves. Previous s…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Patients undergoing traumatic amputation of a single or multiple digits at MGB * English-speaking Exclusion Criteria: * Patients undergoing revision amputation or non-traumatic amputation * Patients under 22 years old * Patients who are pregnant and/or breastfeeding * Unable…
Contacts

Abhiram Bhashyam, MD, PhD

(617) 726 - 4700

abhashyam@mgb.org

CONTACT

Sujit Chepuri, BA

(617) 726 - 1569

schepuri@mgh.harvard.edu

CONTACT